Table 3.

Knowledge-base of genotype profile of Taxane treatment good/bad responding patients.

PGx Profile	ABCB1 alias MDR1		CYP2C8*3	CYP3A4*1B	XRCC3	Effects
Rs#code Nucleotide Codon	rs104564 23435C>T I1145I	rs2032582 2677G>T/A A893S	rs10509681 771 A>G# K399R	rs2740574 −392A>G 5′UTR	rs1799794 316A>G T241M
MAF*	T = 0.566	A = 0.43 T = 0.01	G = 0.131	G = 0.015	A = 0.27	Referred to Caucasian Population
Genotype A	CC	GG	TT	AA	AA	Lower neurotoxicity, due to wild type polymorphisms
Genotype B	CT	GT/A	CT or TT	AG or GG	AG	PM for CYP2C8*3, probable toxicity
Genotype C	TT	TT/AA	CT or TT	AG or GG	AG or GG	Very high risk of cumulative Neuropathy caused by high plasma level of taxane due to PM profiles (CYP2C8* and CYP3A4*22) and low high extrusion from the cells (ABCB1). In addition, probable acute neutropenia (XRCC3)

^*MAF, Minor Allele Frequency. PM, poor Metabolizer; source: www.ensembl.org/Multi/Search/Results?q=MAF;_site=ensembl;_page=1;_facet_feature_type=Gene.

^#Design of the primers and probes were made on complementary DNA strand (T > C).

PM, Poor Metabolizer.